###begin article-title 0
###xml 20 80 20 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Calpain 5, Peroxisome proliferator-activated receptor-gamma </italic>
###xml 84 133 84 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Peroxisome proliferator-activated receptor-delta </italic>
Interaction between Calpain 5, Peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Context
###end title 2
###begin p 3
Obesity is a multifactorial disorder, that is, a disease determined by the combined effect of genes and environment. In this context, polygenic approaches are needed.
###end p 3
###begin title 4
Objective
###end title 4
###begin p 5
###xml 75 86 75 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALPAIN 10 </italic>
###xml 96 106 96 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CALPAIN 5 </italic>
To investigate the possibility of the existence of a crosstalk between the CALPAIN 10 homologue CALPAIN 5 and nuclear receptors of the peroxisome proliferator-activated receptors family.
###end p 5
###begin title 6
Design
###end title 6
###begin p 7
Cross-sectional, genetic association study and gene-gene interaction analysis.
###end p 7
###begin title 8
Subjects
###end title 8
###begin p 9
The study sample comprise 1953 individuals, 725 obese (defined as body mass index >/= 30) and 1228 non obese subjects.
###end p 9
###begin title 10
Results
###end title 10
###begin p 11
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
In the monogenic analysis, only the peroxisome proliferator-activated receptor delta (PPARD) gene was associated with obesity (OR = 1.43 [1.04-1.97], p = 0.027). In addition, we have found a significant interaction between CAPN5 and PPARD genes (p = 0.038) that reduces the risk for obesity in a 55%.
###end p 11
###begin title 12
Conclusion
###end title 12
###begin p 13
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
Our results suggest that CAPN5 and PPARD gene products may also interact in vivo.
###end p 13
###begin title 14
Introduction
###end title 14
###begin p 15
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1032 1033 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1034 1035 1034 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 48 53 <span type="species:ncbi:9606">human</span>
Obesity, which is among of the most hereditable human conditions (45-75%), is, with few exceptions, a polygenic disorder determined by an unknown number of genes with mild to moderate individual effects that also interacts with the environment to produce the phenotype. The importance of the genetic component in obesity has been assessed by the observation of familial aggregation, prevalence differences among ethnic groups and concordance rates in twin studies [1]. Association analysis has been the more successful strategy for the identification of these genetic factors, but these studies are not always replicated in subsequent analyses and only a small proportion of these genes have been consistently associated with the disease [2]. This situation is mainly due to small single gene effects, reason why, genetic association analysis can be strongly influenced by sample size, population structure and allele frequency. Thus, the polygenic approach is arising as the next landmark for the study of common complex diseases [3,4].
###end p 15
###begin p 16
###xml 357 358 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 436 437 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 440 446 420 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 558 564 538 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pparg </italic>
###xml 615 621 595 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 688 689 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 690 691 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 926 927 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1003 1009 983 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 1100 1106 1080 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 1288 1290 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
The peroxisome proliferator-activated receptors (PPARs) belong to a nuclear receptor (NR) superfamily of ligand-inducible transcription factors that form functional complexes with the retinoid x receptors (RXRs). Three subtypes, alpha (alpha), gamma (gamma) and delta (delta), have been identified. PPARalpha (PPARA) is a regulator of fatty acid oxidation [5], whereas PPARgamma (PPARG) mainly functions as a regulator of adipogenesis [6]. PPARG is expressed at adipose tissue, macrophages and muscle where it regulates glucose metabolism. Knockout mice for Pparg are embryonic lethal, but specific deletion of the PPARG gene in fat and muscle has been shown to cause insulin resistance [7,8]. PPARG contributes to the control of energy expenditure by the induction of a futile metabolic cycle in the mitochondria mediated by glycerol kinase and the uncoupling proteins (UCPs), which are transcriptionally regulated by PPARG [9]. Genetic studies have also greatly contributed to corroborate the role of PPARG in the pathogenesis of metabolic syndrome related phenotypes: the Pro12Ala polymorphism of PPARG gene has been confirmed to be associated with greater body mass index (BMI) and insulin sensitivity in the obese subgroup in a recent meta-analysis with more than 32.000 individuals[10].
###end p 16
###begin p 17
###xml 120 122 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 135 141 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppard </italic>
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 464 466 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 467 469 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 472 478 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 527 529 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 530 532 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 596 598 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 599 601 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 635 641 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 739 745 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 825 827 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 828 830 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
In the last few years, PPARdelta (PPARD) has been shown to have a critical role in the regulation of energy metabolism [11]. Increased Ppard expression in adipose tissue in mice has a protective effect against elevated adiposity and serum lipid levels [12]. The activation of PPARD results in the increased expression of genes involved in lipid uptake, fatty acid oxidation and uncoupling proteins, highlighting the PPARD prominent role in mitochondrial activity [13,14]. PPARD gene variants have been associated with obesity [15-17], although some authors have failed to replicate this finding [18-21]. Recent reports have associated PPARD polymorphisms with the effectiveness of cardiovascular fitness, demonstrating the pivotal role of PPARD gene variants in mitochondrial function and, in consequence, in weight control [22,23].
###end p 17
###begin p 18
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 982 1005 982 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Caenorhabditis elegans </italic>
###xml 1024 1031 1024 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 1094 1100 1094 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus </italic>
###xml 1112 1117 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1120 1122 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1303 1305 1303 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1405 1407 1402 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1672 1674 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1681 1688 1678 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN10 </italic>
###xml 1709 1714 1706 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5</italic>
###xml 1762 1764 1759 1761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1765 1767 1762 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1811 1817 1808 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 2010 2016 2007 2013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 982 1004 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 1741 1747 <span type="species:ncbi:9606">humans</span>
###xml 1924 1929 <span type="species:ncbi:9606">women</span>
The calpain family comprises a heterogeneous group of cysteine proteases with a broad expression pattern that includes multiple isoforms that are both ubiquitous and tissue specific. Calpains are involved in a variety of calcium-regulated cellular processes, such as signal transduction, cell proliferation and differentiation, and apoptosis [24]. The calpain role in apoptosis is related to the proteolytic cleavage of the proapoptotic Bax protein, a member of the Bcl-2 family, and the generation of a potent proapoptotic fragment (Bax/p18), which in turn mediates cytocrome c release and initiates the apoptotic execution; this action occurs in the mitochondria, so calpain activity exists within this cell fraction [25]. Calpain 10 (CAPN10) is a member of this protease family which is included into the atypical calpain subgroup, characterized by the absence of the EF-hand domain distinctive of the classical calpains and the presence of a so-called T domain homologue of the Caenorhabditis elegans TRA-3 calpain. The CAPN10 gene was identified as a type 2 diabetes (T2DM) susceptibility locus by Horikawa et al. [26] and, since then, has been associated with many other related conditions such as polycystic ovary syndrome (PCOS), dyslipidemia, hypertension or increased BMI by different groups [24]. CAPN10 has been related to pancreatic beta-cell apoptosis initiated by the fatty acid palmitate [27]. Later on, CAPN10 protein was identified within the mitochondria: the overexpression of mitochondrial CAPN10 results in mitochondrial swelling and autophagy through the cleavage of Complex I subunits and activation of mitochondrial permeability transition (MPT) [28]. The CAPN10 homologue calpain 5 (CAPN5), was firstly analysed in humans by our group [29,30]. In these studies, we found that specific CAPN5 haplotypes could modify the risk of developing metabolic syndrome and PCOS, a common endocrine disorder in women of reproductive age in which all components of metabolic syndrome are frequent. CAPN5 haplotypes were also shown to be associated with diastolic blood pressure and cholesterol levels and a trend for BMI association was observed.
###end p 18
###begin p 19
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Interestingly, some reports have described proteolytic activity of calpains over the PPARs partners in signalling RXRs at the mitochondria [31,32] and over PPARG at the adipose tissue [33]. On the other hand, transcriptional regulation of calpain activity by PPARG has been also described [34].
###end p 19
###begin p 20
###xml 221 234 221 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5, PPARG </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 612 618 612 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
Our main objective was to investigate the possibility of the existence of a crosstalk between the CAPN10 homologue CAPN5 and NRs of the PPAR family. With this purpose, we have selected highly informative polymorphisms in CAPN5, PPARG and PPARD genes and analysed it in 1953 individuals in relation to the absence or presence of obesity. Additionally, we have investigated the individual contributions of these polymorphisms to the obesity phenotype. We have found that the PPARD polymorphism is associated with obesity in our population. We have also found the existence of genetic interaction between CAPN5 and PPARD genes.
###end p 20
###begin title 21
Methods
###end title 21
###begin title 22
Population
###end title 22
###begin p 23
###xml 250 252 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 253 255 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 500 512 <span type="species:ncbi:9606">participants</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
The study sample comprised 1953 individuals, 725 obese (defined as BMI >/= 30) and 1228 non obese subjects recruited from both a population based study and from outpatient visits to different hospitals in a multicenter study as previously described [35,36]. The referral centres involved in this research are Hospital Universitario de Valme (Sevilla), Hospital Universitario Ramon y Cajal (Madrid), and Hospital Universitario San Carlos (Madrid). Informed written consent was obtained from all study participants. The study protocol was designed in accordance with institutional guidelines for human research and was approved by the Ethics Committees of all referral centres.
###end p 23
###begin title 24
Polymorphisms
###end title 24
###begin p 25
###xml 151 157 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 174 180 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 200 206 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 299 305 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 548 550 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 609 613 607 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN</italic>
###xml 702 703 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 753 754 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 762 768 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 1032 1038 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
In order to perform genetic interaction analyses, we have selected three frequent and highly informative polymorphisms (heterozygosity >/= 40%) within CAPN5 (rs7102149 G/A), PPARG (rs2938392 C/T) and PPARD (rs2076167 A/G, N798N). Since in our previous study the genetic association analysis of four CAPN5 polymorphisms with BMI was not conclusive, we have selected a polymorphism at the second intron of the gene, close to the recombination hot spot observed in this gene region that defines the two haplotypic blocks analysed in our prior report [30]. This polymorphism has been found to be expressed in two CAPN5 mRNAs where it is predicted to encode a tryptophan residue in the wild type state (G, TGG) and a stop codon in the polymorphic state (A, TAG). The PPARG polymorphism is located at the fifth intron of the gene in the same disequilibrium block than the Pro12Ala polymorphism using HapMap data, but have a higher allelic frequency and heterozygosity, being for these reasons more informative than Pro12Ala. The selected PPARD polymorphism encodes an asparagine (Asn) residue in the sixth exon of the gene.
###end p 25
###begin title 26
Genotyping
###end title 26
###begin p 27
###xml 46 54 <span type="species:ncbi:9606">patients</span>
We obtained 5 ml of peripheral blood from all patients and controls to isolate germline DNA from leukocytes. DNA extraction was performed in a MagNa Pure LC Instrument (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. To perform polymerase chain reactions (PCRs), we prepared aliquots of DNA at a concentration of 5 ng/mul. The rest of the stock was cryopreserved at -20degreesC.
###end p 27
###begin p 28
###xml 211 213 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
PCR reactions were run on a thermal cycler machine (MJ Research Inc., Waltman, Masachusetts, USA) using a final volume of 20 mul. The genotypes were carried out by using the pyrosequencing technology protocols [37]. The selected primers for pyrosequencing analysis are shown in Table S1. The pyrosequencing machine was programmed in accordance with the manufacturer's recommendation (Biotage, Uppsala, Sweden).
###end p 28
###begin p 29
A 10% of the samples were re-extracted and retyped as an internal control of the quality of the genotyping with a concordance rate of > 99%.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 148 153 <span type="species:ncbi:9606">Human</span>
To analyze deviation from Hardy-Weinberg equilibrium, we used tests adapted from Sasieni [38] at the online resource available at the Institute for Human Genetics, Munich, Germany .
###end p 31
###begin p 32
Logistic regression analysis was used to calculate individual and combined gene effects. For testing gene-gene interactions, we introduced and interaction term within the logistic regression model along with the univariate terms. All analyses have been adjusted for age, sex, smoking (defined as present or past history of smoking of at least five cigarettes per day for a minimum of 5 years), alcohol consumption (defined as a daily intake of more than 10 g) and physical activity. Power calculations suggest that we have 90% power at a significance level of 0.05 to detect an OR for obesity of 1.5.
###end p 32
###begin title 33
Statement of Ethics
###end title 33
###begin p 34
###xml 104 109 <span type="species:ncbi:9606">human</span>
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
Monogenic association analysis
###end title 36
###begin p 37
###xml 79 91 79 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 locus </italic>
###xml 146 158 146 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG locus </italic>
###xml 216 227 216 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD locus</italic>
###xml 471 477 471 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
The observed allele frequencies were 0.63 in controls and 0.64 in cases at the CAPN5 locus (p = 0.456), 0.54 in controls and 0.53 in cases at the PPARG locus (p = 0.340) and 0.72 in controls and 0.69 in cases at the PPARD locus, showing the polymorphic allele at this last gene a slight over-representation in the obese subgroup (p = 0.021). All genotype frequencies are in accordance with the Hardy-Weinberg equilibrium law (p > 0.301) except for the cases group at the PPARG locus, with a slight deviation from the expected proportions (p = 0.037).
###end p 37
###begin p 38
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 116 126 116 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG loci</italic>
###xml 184 196 184 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD locus </italic>
###xml 281 283 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
In the quantitative genotypic association analysis (Table 1), we didn't observe significant differences at CAPN5 or PPARG loci, whereas homozygotes for the polymorphic G allele at the PPARD locus have slightly greater BMI than individuals carrying at least one A allele (28.88 kg/m2 vs 28.12 kg/m2, p = 0.033).
###end p 38
###begin p 39
Quantitative association analysis of the selected polymorphisms with BMI.
###end p 39
###begin p 40
Data are means +/- std. error. Number in brackets are p values (1 df) resulting from the comparison of each genotype against the remaining genotypes. CAPN5, allele 1:G, allele 2: A; PPARG, allele 1: C, allele 2: T; PPARD, allele 1:A, allele 2: G
###end p 40
###begin p 41
###xml 127 139 127 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD locus </italic>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 311 317 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
According to allelic frequencies and quantitative association analysis, the homozygous presence of the polymorphic G allele at PPARD locus is more common in the obese subgroup (OR = 1.43 [1.04-1.97], p = 0.027) (Table 2). No association was observed for the analysed polymorphisms at the CAPN5 (p >/= 0.126) or PPARG (p >/= 0.199) genes.
###end p 41
###begin p 42
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
Genetic association analysis of CAPN5 and PPARD gene variants with obesity.
###end p 42
###begin title 43
Interaction analysis
###end title 43
###begin p 44
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 284 296 284 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 locus </italic>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5</italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
We didn't find evidence of interaction between PPARD and PPARG (p = 0.602), whereas a trend was observed for PPARG and CAPN5 genes (p = 0.056). Regarding PPARD and CAPN5 genes, we detected a significant genetic interaction between the homozygous presence of the polymorphic allele at CAPN5 locus and the wild type at PPARD locus (CAPN5_AA*PPARD_AA, p = 0.038) (Table 3 and figure 1). When compared with non carriers of any of the two genotypes, only the individuals carrying both genotypes are significantly less frequently obese (OR = 0.55 [0.35-0.85], p = 0.008).
###end p 44
###begin p 45
Odds ratio (OR) for obesity in the presence/absence of PPARD_AA and CAPN5_AA genotypes.
###end p 45
###begin p 46
P value for interaction = 0.038
###end p 46
###begin p 47
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Odds ratio (95% confidence interval) for the genetic interaction between the PPARD and CAPN5 genes in obesity.</bold>
Odds ratio (95% confidence interval) for the genetic interaction between the PPARD and CAPN5 genes in obesity. Significant genetic interaction between the homozygous presence of the polymorphic allele at CAPN5 locus and the wild type at PPARD locus (CAPN5_AA*PPARD_AA), OR= 0.55; P value for interaction = 0.038)
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppard </italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 425 431 425 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 862 868 862 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1466 1472 1466 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 145 160 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
The PPARD receptor has a well established role in lipid metabolism, but its implication in the modulation of lipid stores is more controversial. Transgenic mice with targeted activation of Ppard in adipose tissue are resistant to both high-fat diet-induced and genetically predisposed (db/db) obesity; treatment of db/db mice with the PPARD agonist GW501516 also reversed obesity [11]. Several groups have examined different PPARD gene polymorphism in obesity related traits, half of them with positive results. All but two of these reports are limited to a SNP located at the 5'-UTR region of the exon 4 (rs2016520, referred as T+294C or c.-87T>C); this polymorphism is located at the linkage disequilibrium (LD) block adjacent to that of the N798N SNP analysed in the present work [16-19]. In the other two reports, tag SNPs throughout the genomic sequence of PPARD gene were explored, but only one of them obtained positive results [15,20]. The polymorphism analysed by our group has only been explored in the work by Grarup et al. [20], who didn't find association with obesity but identified an haplotype consisting of the rare alleles of this SNP and the rs2076169 polymorphism, located upstream in the same LD block, that was associated with a greater insulin sensitivity. We have not found evidence of the N798N polymorphism being associated with glucose levels or HOMA values in our population (data not shown). The identification of genetic association of PPARD with obesity in our population contributes to the notion that this gene is a candidate gene for obesity and related phenotypes.
###end p 49
###begin p 50
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 514 520 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG </italic>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 871 882 871 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG gene </italic>
###xml 358 361 <span type="species:ncbi:9606">men</span>
We have not found association of the PPARG selected polymorphism with obesity in this population. We selected this polymorphism because is more informative than Pro12Ala and is in the same LD block. Only two works have previously analysed the Pro12Ala polymorphism in Spanish population [39,40]. In one of them, association with obesity was observed only in men (210 individuals) whereas in the other report, statistical significance was only achieved when physical activity was taken into account. Taken together,PPARG does not seem to be a major locus for obesity in our population. Regarding insulin sensitivity, we have not found association of this polymorphism with fasting insulin levels nor HOMA values. However, previous studies in Spanish population have associated the Pro12Ala polymorphism with estimates of insulin sensitivity [39,41], so we can no rule out PPARG gene as a genetic factor influencing insulin action in our population.
###end p 50
###begin p 51
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus </italic>
###xml 311 317 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
The association analysis at the CAPN5 did not contribute to elucidate if this gene has, per se, a role in obesity, since we did not found statistical significant differences at this locus between controls and cases (p >/= 0.126). Thus, this polymorphism, which is predicted to encode a stop codon in one of the CAPN5 mRNAs identified so far, doesn't seem to be a functional variant involved in obesity.
###end p 51
###begin p 52
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CAPN5 </italic>
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD </italic>
###xml 709 711 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 712 714 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 715 717 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 964 966 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1198 1200 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1290 1292 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1332 1334 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1575 1577 1572 1574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1929 1931 1925 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
The most relevant result of our work is the identification of genetic interaction between CAPN5 and PPARD genes. The physiological mechanism underlying the observed interaction is unknown, but we postulate that it could be related to mitochondrial biology. The existence of calpain activity in the mitochondria is a well known fact thanks to the extensive investigations performed in the field of apoptosis, one of the more relevant calpain biological activities. In this way, the CAPN5 homologue, CAPN10, has been shown to exist within the mitochondria and to be involved in pancreatic beta-cell apoptosis, a process postulated to underlie the association of this gene with the insulin resistance phenotype [27,28,42]. On the other hand, mitochondrial versions of NRs have been identified, including the PPARG and the thyroid hormone receptor A (THRA) that is also a RXR partner in signalling, although the existence of the latter is still a controversial issue [43]. Moreover, some reports have described proteolytic activity of calpains over members of the PPAR and RXR families related to the generation of mitochondrial versions of these receptors that regulate mitochondrial gene expression [31]. Proteolytic cleavage of RXR by calpains has been also observed in hepatoma cell lines [32]. Recently, a report by Yajima et al. [33] describes that calpain system regulates the differentiation of adult primitive mesenchymal ST-13 adipocytes through the cleavage of PPARG. On the other hand, transcriptional regulation of calpain activity by PPARG has been also described [34]. In this way, a recent report has shown that the PPARG agonist rosiglitazone reduces mu-calpain activity, normalizing platelet endothelial cell adhesion molecule-1 levels and partially restoring platelet sensitivity to nitric oxide synthase inhibition in type 2 diabetic subjects, a mechanism related to the anti-atherogenic properties of this drug [44]. Although our results regarding CAPN5 and PPARG interaction are not conclusive, we can not rule out the possibility that exits given the statistical trend observed, the similitude between the PPAR family members and the existent bibliography. Further analysis in bigger populations or in other phenotypes besides functional studies will help to clarify this issue.
###end p 52
###begin p 53
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
The existence of calpain activity over NRs, could exist not only inside the mitochondria, but also in the nucleus, being a possible biological explanation for the unusual presence of proteases into the nucleus; this cellular location has been observed for both CAPN5 and CAPN10 among other calpains [45]. Several authors have described calpain activity over diverse NRs including the androgen receptor [46,47] and the estrogen receptors (ERs) [48,49]. Interestingly, mitochondrial versions of the ERs have been also described [43]. Conversely, several NRs modulate the expression of calpains: retinoids, the ligands for retinoid acid receptors (RARs), estrogens, that mediates their action through the estrogen receptors (ERs) and the 1,25-dihydroxyvitamin D3, which uses the vitamin D receptor (VDR), have shown to regulate calpain activity [50-54].
###end p 53
###begin p 54
###xml 301 309 <span type="species:ncbi:9606">patients</span>
Interaction genetic analysis can help to identify genetic factors that when acting together, modify the risk of suffering from a complex disease and contribute to elucidate the molecular mechanism of the studied disease. This knowledge could have direct implications in the clinical management of the patients, heading the pharmacological therapy to the most suitable biological process. We propose that the pathological mechanism of CAPN5 and, perhaps, its homologue CAPN10, could be related to the existence of a cross-talk between this calpain and the RXRs/PPARs nuclear receptors, which are key proteins in the intermediate metabolism and major pharmacological targets. For one hand, CAPN5 regulates these NRs levels and, on the other hand, the NRs regulate CAPN5 level through the induction/repression of its expression. However, functional studies are needed to investigate if the proposed mechanism could be plausible in living cells and if true, pharmacological implications for PPAR agonist should be explored.
###end p 54
###begin title 55
Competing interests
###end title 55
###begin p 56
The authors declare that they have no competing interests.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
MES and RRL have genotyped samples, analysed and interpreted data and draft the manuscript, FJM, AG-P and AR have contributed to conception and design of the study and revised the manuscript, AG, LM MTML, JSH and MSR have contributed to the acquisition and interpretation of data and revised the manuscript.
###end p 58
###begin title 59
Acknowledgements
###end title 59
###begin p 60
###xml 30 38 <span type="species:ncbi:9606">patients</span>
We are deeply grateful to the patients and controls for their participation in this study. We are also very grateful to Mari Carmen Rivero, Juan Velasco and Ana Salinas for their technical work and to Eva Molero and Concha Moreno for data analysis support.
###end p 60
###begin article-title 61
###xml 16 21 <span type="species:ncbi:9606">human</span>
The genetics of human obesity
###end article-title 61
###begin article-title 62
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human obesity gene map: the 2005 update
###end article-title 62
###begin article-title 63
Polygenic contribution to obesity: genome-wide strategies reveal new targets
###end article-title 63
###begin article-title 64
Genetic and environmental interactions in obesity and type 2 diabetes
###end article-title 64
###begin article-title 65
The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression
###end article-title 65
###begin article-title 66
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer
###end article-title 66
###begin article-title 67
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle
###end article-title 67
###begin article-title 68
Muscle-specific Pparg deletion causes insulin resistance
###end article-title 68
###begin article-title 69
Retinoid x receptor heterodimers in the metabolic syndrome
###end article-title 69
###begin article-title 70
Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals
###end article-title 70
###begin article-title 71
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
###end article-title 71
###begin article-title 72
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome
###end article-title 72
###begin article-title 73
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Activation of PPARdelta alters lipid metabolism in db/db mice
###end article-title 73
###begin article-title 74
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
###end article-title 74
###begin article-title 75
Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity
###end article-title 75
###begin article-title 76
Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V
###end article-title 76
###begin article-title 77
###xml 113 118 <span type="species:ncbi:9606">women</span>
Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women
###end article-title 77
###begin article-title 78
###xml 115 123 <span type="species:ncbi:9606">patients</span>
The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls
###end article-title 78
###begin article-title 79
Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians
###end article-title 79
###begin article-title 80
###xml 137 143 <span type="species:ncbi:9606">people</span>
Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people
###end article-title 80
###begin article-title 81
Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS Study
###end article-title 81
###begin article-title 82
Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study
###end article-title 82
###begin article-title 83
Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention
###end article-title 83
###begin article-title 84
The therapeutic potential of the calpain family: new aspects
###end article-title 84
###begin article-title 85
N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death
###end article-title 85
###begin article-title 86
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
###end article-title 86
###begin article-title 87
RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets
###end article-title 87
###begin article-title 88
Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction
###end article-title 88
###begin article-title 89
Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome
###end article-title 89
###begin article-title 90
Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels
###end article-title 90
###begin article-title 91
Endocrine regulation of mitochondrial activity: involvement of truncated RXRalpha and c-Erb Aalpha1 proteins
###end article-title 91
###begin article-title 92
Limited degradation of retinoid X receptor by calpain
###end article-title 92
###begin article-title 93
Calpain system regulates the differentiation of adult primitive mesenchymal ST-13 adipocytes
###end article-title 93
###begin article-title 94
Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages
###end article-title 94
###begin article-title 95
[Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia]
###end article-title 95
###begin article-title 96
Sex and body mass index specific regulation of blood pressure by CYP19A1 gene variants
###end article-title 96
###begin article-title 97
Real-time DNA sequencing using detection of pyrophosphate release
###end article-title 97
###begin article-title 98
From genotypes to genes: doubling the sample size
###end article-title 98
###begin article-title 99
Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population
###end article-title 99
###begin article-title 100
###xml 84 92 <span type="species:ncbi:9606">children</span>
Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents
###end article-title 100
###begin article-title 101
Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid
###end article-title 101
###begin article-title 102
Mitochondrial calpain 10 activity and expression in the kidney of multiple species
###end article-title 102
###begin article-title 103
Mitochondrial nuclear receptors and transcription factors: Who's minding the cell?
###end article-title 103
###begin article-title 104
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and {micro}-Calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone
###end article-title 104
###begin article-title 105
Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus
###end article-title 105
###begin article-title 106
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence
###end article-title 106
###begin article-title 107
Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells
###end article-title 107
###begin article-title 108
Action of calpain on the basic estrogen receptor molecule of porcine uterus
###end article-title 108
###begin article-title 109
Possible involvement of calpain in the growth of estrogen receptor positive breast cancer cells
###end article-title 109
###begin article-title 110
###xml 65 71 <span type="species:ncbi:10090">murine</span>
Inhibitory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through suppression of deregulated calpains
###end article-title 110
###begin article-title 111
Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis
###end article-title 111
###begin article-title 112
Oestrogen receptor subtype-specific repression of calpain expression and calpain enzymatic activity in neuronal cells--implications for neuroprotection against Ca-mediated excitotoxicity
###end article-title 112
###begin article-title 113
[Prevalence of obesity in Spain: results of the SEEDO 2000 study]
###end article-title 113
###begin article-title 114
Vitamin D-induced apoptosis and melanoma: does calpain represent the major execution protease rather than caspases?
###end article-title 114

